Allogene Therapeutics, Inc. (ALLO): Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Allogene (ALLO) reported a Q2 2026 net loss of $42.7M, or $0.13 per share, with $4.6M in collaboration revenue. Cash reserves totaled $423.6M, providing a runway into 2029. Key clinical updates include 58.3% MRD negativity in the ALPHA3 trial and a 31% ORR for ALLO-316. The company aims to expand access to CAR T therapies in community settings. FDA granted RMAT and Fast Track designations for cema-cel. Management highlighted upcoming milestones and risks, including small data sets and safety cha

Allogene Therapeutics (ALLO) reported Q2 2026 EPS loss of 13 cents, narrower than the Zacks Consensus loss of 16 cents, helped by lower R&D costs. Collaboration revenue from related parties was $4.6 million. Cash, cash equivalents and investments rose to $423.6 million after a $200.4 million April offering. The company reiterated 2026 operating expense guidance and expects ALPHA3 interim EFS data in mid-2027.

Allogene Therapeutics, Inc. (ALLO) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Allogene Therapeutics Reports Second Quarter 2026 Financial Results and Business Update • Pivotal Phase 2 ALPHA3 Program in 1L Large B-cell Lymphoma (LBCL): ◦ Recent Interim Futility Analysis Supports Cemacabtagene Ansegedleucel’s (Cema-Cel) Potential as an Outpatien

CoreWeave Inc. (CRWV) has a $2.6B AI infrastructure loan with a risk of early repayment if customer contract breaches occur. Lenders focus on service-level agreements (SLAs) to avoid downtime threats. Poor performance can lead to contract terminations, triggering early debt repayment. The loan, priced at SOFR + 5.5%, has a five-year term but is backed by shorter customer contracts.

Norwegian Cruise Line Holdings (NCLH) stock is down 32% this year, underperforming rivals Carnival (CCL) and Royal Caribbean (RCL). NCLH cited record bookings and announced a $750M debt refinancing. Higher debt and fuel costs may explain its sharper decline. Investors await Q3 results and energy price trends.

SpaceX is seeking $40 billion in financing, including $10 billion in bank loans and $30 billion in debt, to buy Nvidia AI chips. According to Reuters, the company is discussing the financing with banks and asset managers like PIMCO and Apollo. The funds will support SpaceX's AI infrastructure expansion, with plans to double Nvidia chip usage by December.